Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Nicholas Ah Mew is a medical advisor to the National Urea Cycle Disorders Foundation and Citrin Foundation, serves on the Data Safety Monitoring Board of clinical trials conducted by iECURE and Arcturus Therapeutics, and is a consultant to Ultragenyx Pharmaceutical and Moderna
It is notable that neither the GLP-1R antagonist exendin(939) nor the GRA REMD2.59 had any (major) effect on glucagon secretion at 1 mmol/l glucose, making it unlikely that glucagon secretion is under significant autocrine control by glucagon or GLP-1(736) [63, 64] from alpha cells
I don't want to tell you the wrong
Therefore, DEX-mediated increase in uric acid excretion is mainly due to the downregulation effect of URAT1 (Li et al., 2019)
.webp)
US$ 26.89
US$ 22.52
US$ 26.74
US$ 22.98
,aspect=ignore)
